Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on July 31, 2026. A total of 21,121,396 shares of voting common stock, or approximately 75% of the 28,009,802 shares outstanding as of June 5, 2026, were represented virtually or by proxy.
For the election of two Class II directors, stockholders cast 9,273,875 votes for and 419,763 withheld for Judith Shizuru, M.D., Ph.D., and 9,280,610 votes for and 413,028 withheld for Tom Wiggans, with 11,427,758 broker non-votes for each nominee. On the proposal to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, votes totaled 20,635,404 for, 434,262 against, and 51,730 abstentions. On the advisory vote regarding compensation of named executive officers, stockholders cast 9,016,797 votes for, 604,173 against, 72,668 abstentions, and 11,427,758 broker non-votes.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented at 2026 Annual Meeting: 21,121,396 shares
Shares outstanding as of record date: 28,009,802 shares
Approximate participation rate: 75%
+4 more
7 metrics
Shares represented at 2026 Annual Meeting
21,121,396 shares
Voting common stock represented virtually or by proxy on July 31, 2026
Shares outstanding as of record date
28,009,802 shares
Voting common stock issued and outstanding as of June 5, 2026
Approximate participation rate
75%
Portion of voting common stock represented at the 2026 Annual Meeting
Votes for Judith Shizuru, M.D., Ph.D.
9,273,875 votes
Votes cast for Class II director nominee at 2026 Annual Meeting
Votes for Tom Wiggans
9,280,610 votes
Votes cast for Class II director nominee at 2026 Annual Meeting
Votes for auditor ratification
20,635,404 votes
Votes for ratifying PricewaterhouseCoopers LLP for fiscal year ending December 31, 2026
Votes for say-on-pay proposal
9,016,797 votes
Votes for advisory approval of compensation of named executive officers
Key Terms
Class II directors, independent registered public accounting firm, advisory basis, broker non-votes, +1 more
5 terms
Class II directors regulatory
"To elect two Class II directors to serve until the 2029 annual meeting"
independent registered public accounting firm regulatory
"to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory basis regulatory
"To approve, on an advisory basis, the compensation of the Company’s named executive officers"
broker non-votes regulatory
"Broker Non-Votes column showed 11,427,758 broker non-votes for each nominee"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company status under Rule 12b-2 of the Securities Exchange Act"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What quorum was achieved at Jasper Therapeutics (JSPR) 2026 annual meeting?
Jasper Therapeutics reported 21,121,396 shares of voting common stock represented at its 2026 annual meeting, equal to approximately 75% of the 28,009,802 shares outstanding as of the June 5, 2026 record date, satisfying typical quorum requirements.
How many votes did Jasper Therapeutics (JSPR) Class II director nominees receive in 2026?
For the 2026 Class II director elections, stockholders cast 9,273,875 votes for Judith Shizuru, M.D., Ph.D., and 9,280,610 votes for Tom Wiggans, with 419,763 and 413,028 votes withheld, respectively, plus 11,427,758 broker non-votes for each nominee.
What were the 2026 auditor ratification vote results for Jasper Therapeutics (JSPR)?
On ratifying PricewaterhouseCoopers LLP as Jasper Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026, stockholders cast 20,635,404 votes for, 434,262 against, and 51,730 abstentions, indicating strong support in the overall vote distribution.
How did Jasper Therapeutics (JSPR) stockholders vote on 2026 executive compensation?
In the 2026 advisory vote on compensation of named executive officers, Jasper Therapeutics stockholders cast 9,016,797 votes for, 604,173 against, and 72,668 abstentions, with an additional 11,427,758 broker non-votes reported in the tally for this advisory proposal.